



Epilepsy!



INTRODUCING Clonam (Clonazepam)

INDICATIONS:¹

All clinical forms of epileptic disease in children or adults, especially typical or atypical petit mal, focal seizures with elementary or complex symptomatology, generalised primary or secondary tonic-clonic seizures, status epilepticus in all its clinical forms.

PHARMACOLOGICAL ACTION:¹

Pharmacodynamic properties:

- ▶ Anticonvulsive
- ▶ Sedative
- ▶ Muscle relaxing
- ▶ Anxiolytic

Pharmacokinetic properties:

- ▶ Peak plasma 1 - 4 hours after an oral dose
- ▶ Bioavailability 90 % after oral administration



References: 1. Clonam 0.5 & Clonam 2 (Tablets) approved Package Insert: 11 June 2015.
 Clonam 0.5 (Tablets). Each Clonam 0.5 tablet contains 0.5 mg Clonazepam. Reg. No. 45/2.5/0820. Clonam 2 (Tablets). Each Clonam 2 tablet contains 2 mg Clonazepam. Reg. No. 45/2.5/0821. For full prescribing information refer to the package insert approved by the Medicines Regulatory Authority.
Applicant: Pharmadyne Healthcare (Pty) Ltd. Co. Reg. No.: 1962/002457/07. 07 Rossini Street, Van der Hoffpark, Potchefstroom, 2531. Telephone +27 18 290 5706. Facsimile 086 265 0191.
Marketed by: Ascendis Pharma (Pty) Ltd. Co. Reg. No.: 2012/021486/07. Telephone +27 11 857 2090. Facsimile 086 664 6223.